Disclaimer statement
Warning!
Partnership news
2025
Guangdong, China and Bagsværd, Denmark, 24 March 2025
Cambridge, Mass., March 3, 2025
Tokyo, Japan, Feb. 3, 2025
Heartseed Inc. today announced the completion of patient enrollment for the 5th patient in high-dose arm, marking the 10th and final patient enrolled in its Phase I/II clinical trial (LAPiS Study) for HS-001, an allogeneic iPS cell-derived cardiomyocyte spheroid product for advanced heart failure due to ischaemic heart disease.
Durham, N.C., Jan. 22, 2025
IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions
Bagsværd, Denmark and Lexington, Massachusetts, US, 8 January 2025
Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI).
Seattle, Wash., 7 January 2025
Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease.
The partnership between Novo Nordisk and Variant Bio is aimed at identifying and validating multiple novel targets with sufficient human genetic evidence to initiate human-centric drug discovery programs.
2024
Bagsværd, Denmark, 18 December 2024
Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalisation of Novo Holdings’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US).
Waltham, Mass., 18 December 2024
Photys Therapeutics, Inc., a proximity-based therapeutics company, today announced a multi-year collaboration and license agreement with Novo Nordisk to develop novel proximity-based therapeutics for a cardiometabolic disease target.
Hamburg, Germany, 11 December 2024
Evotec SE announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center.
Cambridge, Mass., 10 December 2024
Eikonizo Therapeutics, a biopharmaceutical company dedicated to developing disease-modifying therapies to improve the lives of people impacted by neurodegenerative and cardiorenal diseases announced today that it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative.
Bagsværd, Denmark, December 6, 2024
Today, the European Commission approved Novo Holdings A/S’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk’s subsequent acquisition of three manufacturing sites from Novo Holdings A/S.
The agreement to acquire the three manufacturing sites was announced on 5 February 2024.
For further information, please see the company announcement here.
Copenhagen, Denmark, November 4, 2024
Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.
Hamburg, Germany, 26 September 2024
Evotec SE announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.
Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on development of advanced technologies in support thereof.
Ghent, Belgium, 19 September 2024
Tanai Therapeutics, a VIB spin-off company developing a new therapeutic class of obesity treatments, today announces it has secured additional financing from Novo Nordisk A/S and BioGeneration Ventures (“BGV”) alongside existing investors V-Bio Ventures, Qbic and VIB, bringing the total seed round to date to over EUR 6 million. Tanai is developing an oral therapeutic targeting a novel, genetically validated pathway in obesity that plays a key role in energy expenditure.
Vancouver, British Columbia., September 18, 2024
NanoVation Therapeutics Inc., a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced a multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases.
The partnership combines NanoVation Therapeutic’s proprietary long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery to cells outside of the liver with Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical translation.
Cambridge, Mass., September 16, 2024
Korro Bio, Inc. (Korro), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases, today announced a collaboration with Novo Nordisk, a global healthcare company, to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases.
The collaboration brings together Novo Nordisk’s deep cardiometabolic disease understanding and drug development experience with Korro’s proprietary platform to develop RNA editing product candidates for two undisclosed targets.
New York, USA – 10 September 2024
Kallyope, a clinical stage biotechnology company discovering and developing novel therapies for diseases with high unmet need, today announced that under the terms of its research collaboration with Novo Nordisk to discover novel peptide therapeutics, a ligand identified by Kallyope has been licensed by Novo Nordisk for further development, including as a potential new mechanism for the treatment of obesity.
Cambridge, Mass., June 26, 2024
2seventy bio, Inc. announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease.
Heidelberg, Germany, 19 June 2024
The German Centre for Cardiovascular Research (DZHK) and the Heidelberg University Hospital have entered into a research collaboration with Novo Nordisk to understand and treat dilated cardiomyopathy (DCM). This severe heart disease often leads to heart failure. The project focuses on identifying treatment options that address the cause of the disease and not just the symptoms.
San Diego, June 13, 2024
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of DYRK/CLK kinases, has entered a collaboration with Novo Nordisk to develop drug candidates for the treatment of diabetes. This agreement builds upon Biosplice’s innovative research, supported by robust external scientific literature, demonstrating the potential of DYRK inhibition to stimulate β-cell proliferation in animal models and human islet cells, thus offering a promising avenue for diabetes treatment. The collaboration combines Novo Nordisk’s expertise in diabetes and Biosplice’s research and development efforts focused on creating selective and potent DYRK inhibitors.
Cambridge, Mass., May 9, 2024
Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today joined Flagship Pioneering in announcing a research collaboration with Novo Nordisk to develop up to two next-generation therapeutics for obesity management.
Waltham, Mass. & Montreal, May 3, 2024
Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE™, to develop differentiated small molecule therapeutics, today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor licensed by Novo Nordisk in September 2022.
Boston, 10 April 2024
Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D partnership. Together, the two companies aim to improve the manufacturing of Novo Nordisk’s medicines for serious chronic diseases, including diabetes and obesity medications.
Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024
Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.
San Diego, February 26, 2024
Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degraders. Neomorph, a biotechnology company solving critical problems in human health through the discovery of novel therapeutics against 'undruggable' targets, was founded in 2020 and is venture backed by Deerfield Management Company.
Barcelona, Spain. February 19, 2024
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828. Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases.
Bagsværd, Denmark, 5 February 2024
Novo Nordisk today announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in Somerset, New Jersey (US). Novo Nordisk and Catalent have a long-standing collaboration.
Schlieren, Switzerland, 23 January 2024
EraCal Therapeutics Ltd. today announced that it has entered into a collaboration and license agreement with Novo Nordisk A/S to develop and commercialize EraCal’s oral, small molecule program.
Bagsværd, Denmark, Cambridge and Somerville, USA, 4 January, 2024
Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company.
2023
Dublin, Ireland, 14 December 2023
Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company.
Marseille, France, 30 October 2023
Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S.
Chicago, USA, 19 October 2023
GE HealthCare (Nasdaq: GEHC) today announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound (PFUS).
Bagsværd, Denmark and Singapore, 16 October 2023
Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars.
Cambridge, USA and Hamburg, Germany, 26 September 2023
Novo Nordisk and Evotec SE, today announced LAB eN² (pronounced Lab ee – en – squared), a translational drug discovery accelerator that aims to nurture early research from academic institutions into novel therapeutics.
Bagsværd, Denmark and Boston, Massachusetts, US, 25 September 2023
Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases based on Valo’s large human dataset and computation powered by artificial intelligence (AI).
Cambridge, USA, 6 September 2023
The Broad Institute of MIT and Harvard today announced a new research alliance with Novo Nordisk aimed at addressing critical unmet clinical needs in diabetes and cardiometabolic diseases.
Copenhagen, Denmark, 30 August 2023
Embark Laboratories announced today that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a three-year research and development collaboration to discover and develop novel pharmaceuticals to treat obesity and related co-morbidities.
Bagsværd, Denmark and Montreal, Canada, 10 August 2023
Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.
Read all the details about our acquisition of Inversago
Bagsværd, Denmark and Issoire, France, 5 June, 2023
Novo Nordisk A/S and BIOCORP Production SA announced today that Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which would be followed by a mandatory simplified tender offer on all remaining outstanding shares in BIOCORP1 at a price of 35.00 Euros per share in cash, representing a total equity value of approximately 154 million Euros.
Bagsværd, Denmark and Durham, USA, 24 May 2023
Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets.
Vancouver, Canada and Bagsværd, Denmark, 12 April 2023
Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity.
